Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2012 1
2013 1
2014 4
2015 2
2016 1
2017 3
2018 5
2019 6
2020 5
2021 5
2022 4
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Differentiated Thyroid Gland Carcinoma"
Page 1
Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Thomas L, et al. Oncologist. 2014 Mar;19(3):251-8. doi: 10.1634/theoncologist.2013-0362. Epub 2014 Feb 21. Oncologist. 2014. PMID: 24563075 Free PMC article. Review.
BACKGROUND: Sorafenib was recently approved by the U.S. Food and Drug Administration for radioiodine-resistant metastatic differentiated thyroid cancer (DTC). In addition, two drugs (vandetanib and cabozantinib) have received U.S. ...METHODS: A systematic rev …
BACKGROUND: Sorafenib was recently approved by the U.S. Food and Drug Administration for radioiodine-resistant metastatic differen …
Rare metastases of well-differentiated thyroid cancers: a systematic review.
Madani A, Jozaghi Y, Tabah R, How J, Mitmaker E. Madani A, et al. Ann Surg Oncol. 2015 Feb;22(2):460-6. doi: 10.1245/s10434-014-4058-y. Epub 2014 Sep 6. Ann Surg Oncol. 2015. PMID: 25192681 Review.
BACKGROUND: A minority of metastatic well-differentiated thyroid cancer (WDTC) patients present with end-organ disease other than in the lung, bone or lymph nodes. ...RESULTS: A total of 492 patients (median age, 62 years [50-70 years]) were identified in 197 …
BACKGROUND: A minority of metastatic well-differentiated thyroid cancer (WDTC) patients present with end-organ disease …
Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis.
Poma AM, Macerola E, Ghossein RA, Tallini G, Basolo F. Poma AM, et al. Thyroid. 2024 Mar;34(3):314-323. doi: 10.1089/thy.2023.0350. Thyroid. 2024. PMID: 38115626
Background: The current edition of the World Health Organization (WHO) classification of endocrine tumors introduced grading for follicular cell-derived thyroid cancer. Tumors with necrosis and/or high mitotic count but not fulfilling the Turin criteria for poorly …
Background: The current edition of the World Health Organization (WHO) classification of endocrine tumors introduced grading for follicular …
Systematic review of site distribution of bone metastases in differentiated thyroid cancer.
Osorio M, Moubayed SP, Su H, Urken ML. Osorio M, et al. Head Neck. 2017 Apr;39(4):812-818. doi: 10.1002/hed.24655. Epub 2017 Jan 11. Head Neck. 2017. PMID: 28079945 Review.
BACKGROUND: Thyroid cancer is the fastest growing cancer in the United States. A small portion of differentiated thyroid cancers (DTCs; 2% to 13%) develop bone metastases, which can decrease a patient's survival rate by more than 60%. ...
BACKGROUND: Thyroid cancer is the fastest growing cancer in the United States. A small portion of differentiated thyroid …
Radioiodine Remnant Ablation for Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.
James DL, Ryan ÉJ, Davey MG, Quinn AJ, Heath DP, Garry SJ, Boland MR, Young O, Lowery AJ, Kerin MJ. James DL, et al. JAMA Otolaryngol Head Neck Surg. 2021 Jun 1;147(6):544-552. doi: 10.1001/jamaoto.2021.0288. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 33792650 Free PMC article.
IMPORTANCE: Postoperative radioactive iodine (RAI) remnant ablation for differentiated thyroid cancer (DTC) facilitates the early detection of recurrence and represents an adjuvant therapy that targets persistent microscopic disease. ...MAIN OUTCOMES AND MEASURES: D …
IMPORTANCE: Postoperative radioactive iodine (RAI) remnant ablation for differentiated thyroid cancer (DTC) facilitates the ea …
Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis.
Vuong HG, Duong UNP, Pham TQ, Tran HM, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T. Vuong HG, et al. World J Surg. 2018 Apr;42(4):1005-1017. doi: 10.1007/s00268-017-4206-1. World J Surg. 2018. PMID: 28913696 Review.
INTRODUCTION: Distant metastasis (DM) is not a frequent event in differentiated thyroid carcinoma (DTC) but has an adverse impact on mortality of patients with DTC. ...
INTRODUCTION: Distant metastasis (DM) is not a frequent event in differentiated thyroid carcinoma (DTC) but has an adve …
Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data.
Ngo TNM, Le TTB, Le T, Bychkov A, Oishi N, Jung CK, Hassell L, Kakudo K, Vuong HG. Ngo TNM, et al. Endocr Pathol. 2021 Dec;32(4):489-500. doi: 10.1007/s12022-021-09692-z. Epub 2021 Sep 24. Endocr Pathol. 2021. PMID: 34559383
Primary (or de novo) anaplastic thyroid carcinoma (ATC) is ATC without pre-existing history of differentiated thyroid carcinoma (DTC) and no co-existing DTC foci at the time of diagnosis. ...We also performed a systematic review and meta-analysi …
Primary (or de novo) anaplastic thyroid carcinoma (ATC) is ATC without pre-existing history of differentiated thyroi …
Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis.
Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M. Shan CX, et al. Laryngoscope. 2012 Apr;122(4):797-804. doi: 10.1002/lary.22162. Epub 2012 Jan 31. Laryngoscope. 2012. PMID: 22294492 Review.
OBJECTIVE/HYPOTHESIS: The role of central neck dissection (CND) remains controversial in differentiated thyroid cancer (DTC). STUDY DESIGN: Systematic review and meta-analysis. ...
OBJECTIVE/HYPOTHESIS: The role of central neck dissection (CND) remains controversial in differentiated thyroid cancer (DTC). …
Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J, Liu Z, Su Y, Peng X, Xie Y. Yu J, et al. Clin Endocrinol (Oxf). 2024 Apr;100(4):379-388. doi: 10.1111/cen.15027. Epub 2024 Feb 13. Clin Endocrinol (Oxf). 2024. PMID: 38351437
A series of trials have demonstrated the antitumor activity of tyrosine kinase inhibitors (TKIs) in radioiodine refractory differentiated thyroid cancer (RAIR-DTC). However, the available evidence cannot determine the optimal choice of TKI in RAIR-DTC. ...CONCLUSION …
A series of trials have demonstrated the antitumor activity of tyrosine kinase inhibitors (TKIs) in radioiodine refractory differentiated …
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.
Ali Hailan YM, Al-Dubai HN, Yassin MA. Ali Hailan YM, et al. Oncology. 2023;101(6):362-368. doi: 10.1159/000530463. Epub 2023 May 9. Oncology. 2023. PMID: 37231874 Free article. Review.
Radioactive iodine (RAI), an established agent in the management of differentiated thyroid carcinomas, has raised concern due to its possible carcinogenic effects. ...We have identified 14 reports and found that most reports were for men under the age of 60 years wi …
Radioactive iodine (RAI), an established agent in the management of differentiated thyroid carcinomas, has raised concern due …
43 results